Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2020
Apr. 30, 2019
Apr. 30, 2020
Apr. 30, 2019
Income Statement [Abstract]        
Revenue $ 250,000 $ 250,000
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 166,250 166,250
Amortization of patents 125,625 376,875
Research and development expenses (including non-cash share-based compensation expenses of $458,132, $655,066, $855,655 and $2,228,845 respectively) 1,228,790 1,269,393 2,719,378 3,516,665
General and administrative expenses (including non-cash share-based compensation expenses of $651,954, $666,384, $1,275,765 and $1,842,769 respectively) 1,441,347 1,281,966 2,580,628 3,348,422
Impairment in carrying amount of patent asset (Note 1) 418,750
Total operating costs and expenses 2,670,137 2,843,234 5,300,006 7,826,962
Loss from operations (2,670,137) (2,593,234) (5,300,006) (7,576,962)
Interest income 12,147 18,300 25,441 35,419
Loss before income taxes (2,657,990) (2,574,934) (5,274,565) (7,541,543)
Provision for income taxes
Net loss (2,657,990) (2,574,934) (5,274,565) (7,541,543)
Less: Net loss attributable to noncontrolling interest (17,897) (37,242) (41,929) (122,010)
Net loss attributable to common shareholders $ (2,640,093) $ (2,537,692) $ (5,232,636) $ (7,419,533)
Net loss per common share attributable to common shareholders:        
Basic and diluted (in Dollars per share) $ (0.12) $ (0.13) $ (0.25) $ (0.38)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 21,155,505 19,645,140 20,927,212 19,403,933